Citius Pharmaceuticals is trading 6.93% up at $0.60, with no clear company-specific announcement identified for September 17, 2026; the move appears aligned with stronger overall market sentiment.
- The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are each higher by more than 0.5%.
- Investor focus remains on LYMPHIR commercialization and Mino-Lok’s FDA review, but neither appears to be a new catalyst for this session.